Coleman, Craig I.; Musial, Bogdan L.; Ross, Jack
April 2003
Formulary;Apr2003, Vol. 38 Issue 4, p204
Academic Journal
Focuses on enfuvirtide, the first member of antiretrovirals to gain U.S. Food and Drug approval for the treatment of HIV-1 infection. Pharmacology; Pharmacokinetics; Clinical trials of enfuvirtide; Safety and tolerability; Drug interactions; Dosage and administration; Cost. INSET: Formulary considerations.


Related Articles

  • FDA Actions.  // Critical Care Alert;Dec2009 Pharmacology Watch, p2 

    The article reports on the approval of the Food and Drug Administration (FDA) on the use of IV antiviral peramivir for treatment of inpatients with 2009 H1N1 influenza in the U.S.

  • New molecular entities/new biologics.  // Formulary;Apr2003, Vol. 38 Issue 4, p182 

    Reports on the U.S. Food and Drug Administration's approval of enfuvirtide, an anti-HIV drug. Efficacy; Safety; Dosing; Availability; Cost.

  • FDA Encourages Combo Product Development. Wechsler, Jill // Applied Clinical Trials;Mar2005, Vol. 14 Issue 3, p28 

    Reports on the approval of a fixed-dose-combination (FDC) treatment for AIDS under a new policy by the U.S. Food and Drug Administration (FDA). Encouragement of combo product development; Modification of preclinical and clinical testing requirements; Development of antiviral FDC specifically for...

  • New class of anti-HIV drug approved.  // European Pharmaceutical Executive;Jun2007, p9 

    The article reports on the recommendation of the U.S. Food and Drug's (FDA) Antiviral Drugs Advisory Committee on the approval of Pfizer Inc.'s maraviroc, a chemokine receptor (CCR5) antagonist. It is designed to treat patients infected with CCR5-tropic human immunodeficiency virus-1 (HIV),...

  • FDA Warnings Dominate Pharmaceutical News. Elliott, William T. // Neurology Alert;Jan2008, Vol. 26 Issue 5, p1 

    Thee article offers updates on the U.S. Food and Drug Administration (FDA). The agency and its advisory committee have issued warnings on several drugs including erythropoiesis-stimulating agents, oseltamivir and zanamivir for the treatment of influenza and rosiglitazone for the treatment of...

  • EUA or eIND? Testing drugs in an emergency.  // IRB Advisor;Jun2010, Vol. 10 Issue 6, p67 

    The article focuses on Emergency Use Authorization (EUA) process and emergency Investigational New Drug (eIND) regulation, drug distribution mechanisms used by the Food and Drugs Administration (FDA). It discusses two mechanisms based on the H1N1 emergency that happened last 2009, where the FDA...

  • Testing, Testing. Ellen, David // New Republic;8/28/89, Vol. 201 Issue 9, p14 

    Presents information related to the drug ddI, the most promising anti-viral AIDS drug to pass initial Phase I human safety tests approval from the U.S. Food and Drug Administration. Comparison of the toxicity of ddI and AZT; Decrease in the amount of AIDS viral material and an increase in the...

  • Siga files application for emergency use of antiviral drug.  // PharmaWatch: Biotechnology;May2008, Vol. 7 Issue 5, p10 

    The article reports on the submission of an application by Siga Technologies Inc. to support an emergency use authorization of its orally active, smallpox antiviral drug ST-246. The emergency use authorization mechanism enables the U.S. Food and Drug Administration (FDA) Commissioner to...

  • ViroPharma Shares Drop as Maribavir Fails Phase III.  // Bioworld Week;2/16/2009, Vol. 17 Issue 7, p3 

    The article reports on the decline of shares of ViroPharma Inc. by 53% due to the failure of its antiviral drug maribavir to meet its primary endpoint of preventing cytomegalovirus (CMV) disease in a Phase III trial in patients undergoing stem cell transplant. It has also failed to hit secondary...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics